title: Transponder-induced sarcoma in the heterozygous p53+/- mouse.
abstract: Heterozygous p53+/- transgenic mice are being studied for utility as a short-term alternative model to the 2-yr rodent carcinogenicity bioassay. During a 26-wk study to assess the potential carcinogenicity of oxymetholone using p-cresidine as a positive control, glass/polypropylene microchips (radio transponder identification devices) were subcutaneously implanted into male and female p53+/- mice. During week 15, the first palpable mass was clinically observed at an implant site. This rapidly growing mass virtually quadrupled in size by week 25. Microscopic examination of all implant sites revealed that 18 of 177 animals had a subcutaneous histologically malignant sarcoma. The neoplasms were characterized as undifferentiated sarcomas unrelated to drug treatment, as indicated by the relatively even distribution among dose groups, including controls. An unusual preneoplastic mesenchymal change characterized by the term "mesenchymal dysplasia" was present in most groups and was considered to be a prodromal change to sarcoma development. The tumors were observed to arise from dysplastic mesenchymal tissue that developed within the tissue capsule surrounding the transponder. The preneoplastic changes, including mesenchymal dysplasia, appeared to arise at the transponder's plastic anchoring barb and then progressed as a neoplasm to eventually surround the entire microchip. Capsule membrane endothelialization, inflammation, mesenchymal basophilia and dysplasia, and sarcoma were considered unequivocal preneoplastic/neoplastic responses to the transponder and were not related to treatment with either oxymetholone or p-cresidine.
authors.affiliation: Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877, USA. kblancha@rdg.boehringer-ingelheim.com
authors.forename: K T
authors.initials: KT
authors.lastname: Blanchard
authors.forename: C
authors.initials: C
authors.lastname: Barthel
authors.forename: J E
authors.initials: JE
authors.lastname: French
authors.forename: H E
authors.initials: HE
authors.lastname: Holden
authors.forename: R
authors.initials: R
authors.lastname: Moretz
authors.forename: F D
authors.initials: FD
authors.lastname: Pack
authors.forename: R W
authors.initials: RW
authors.lastname: Tennant
authors.forename: R E
authors.initials: RE
authors.lastname: Stoll
mesh_terms: D045930:Anabolic Agents / Q000633:toxicity; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006579:Heterozygote; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010110:Oxymetholone / Q000633:toxicity; D011126:Polypropylenes / Q000009:adverse effects*; D012513:Sarcoma, Experimental / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D012867:Skin / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D012878:Skin Neoplasms / Q000209:etiology / Q000235:genetics / Q000473:pathology; D016019:Survival Analysis; D014159:Transducers / Q000009:adverse effects*
chemical_list: D045930:Anabolic Agents; D002273:Carcinogens; D004273:DNA, Neoplasm; D011126:Polypropylenes; D010110:Oxymetholone